A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 14 Aug 2017 According to a Spectrum Pharmaceuticals media release, new study design with a reduced sample size from 1557 to about 425 patients will significantly shorten the duration of this trial.
- 14 Aug 2017 According to a Spectrum Pharmaceuticals media release, first patient has been enrolled.
- 14 Aug 2017 Status changed from planning to recruiting, according to a Spectrum Pharmaceuticals media release.